Sharescart Research Club logo

Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹33208 Cr.
Stock P/E
69
P/B
8.4
Current Price
₹1235.1
Book Value
₹ 147.7
Face Value
2
52W High
₹1455.9
52W Low
₹ 955.2
Dividend Yield
0.04%

Global Health Overview

Business

Global Health Ltd., operating under the brand name Medanta, is one of India's largest private multi-specialty tertiary and quaternary care providers. The company owns and operates a chain of hospitals that offer a wide range of medical services across various specialties including cardiology, cardiac surgery, oncology, neurosciences, liver and digestive diseases, orthopaedics, and kidney and urology. Its core business model revolves around providing comprehensive healthcare services to patients, encompassing inpatient, outpatient, diagnostic, and emergency care. The company generates revenue primarily through patient services, including consultations, surgeries, diagnostic tests, room charges, and pharmacy sales. It also caters to medical tourism patients seeking advanced medical care in India.

Revenue Mix

Global Health Ltd.'s revenue is primarily derived from its hospital services. While specific granular breakdowns may vary, the major components include:

Inpatient Services: Revenue from patients admitted for surgeries, treatments, and prolonged medical care. This typically forms the largest portion.

Outpatient Services: Revenue from consultations, day care procedures, and minor treatments.

Diagnostic Services: Revenue from a wide array of laboratory and imaging tests conducted within its facilities.

Pharmacy Sales: Revenue from medicines dispensed to both inpatient and outpatient customers.

Given its multi-specialty nature, revenue is distributed across various medical departments, with high-end specialties like cardiac sciences, oncology, and neurosciences often contributing significantly.

Industry

The Indian healthcare industry is characterized by a growing demand for quality healthcare services, driven by increasing population, rising disposable incomes, higher prevalence of chronic diseases, and evolving health insurance penetration. It is a mix of public and private providers, with private players like Global Health dominating the tertiary and quaternary care segment. Global Health is positioned as a premium provider of advanced, multi-specialty healthcare, particularly strong in the Delhi-NCR region (Gurugram) and expanding its presence in other key cities. It competes with other large corporate hospital chains such as Apollo Hospitals, Fortis Healthcare, Max Healthcare, and Narayana Hrudayalaya, differentiating itself through its specialist-led approach, state-of-the-art infrastructure, and reputation in complex procedures.

MOAT

Global Health's competitive advantages include:

Brand Reputation: The "Medanta" brand has established a strong reputation for clinical excellence, particularly in complex surgeries and super-specialties, attracting both domestic and international patients.

Talent Pool: Ability to attract and retain highly skilled and renowned doctors and medical professionals, which is crucial in tertiary care. The founder, Dr. Naresh Trehan, himself is a globally recognized cardiac surgeon.

Comprehensive Services: Offering a wide array of super-specialties under one roof, providing integrated care and making it a preferred choice for complex medical conditions.

Infrastructure & Technology: Investment in advanced medical technology and modern infrastructure supports complex procedures and enhances patient outcomes.

Scale and Network (Emerging): While not as vast as some older chains, its strategic expansion provides growing scale and regional dominance, particularly in specific markets.

Growth Drivers

Key factors that can drive Global Health's growth over the next 3-5 years include:

Increasing Healthcare Expenditure: Rising per capita healthcare spending and growing health insurance penetration in India.

Medical Tourism: Continued influx of international patients seeking high-quality, cost-effective advanced medical treatment.

Expansion of Capacity: Commissioning of new beds in existing facilities (e.g., Lucknow expansion) and strategic greenfield/brownfield expansion into new geographies.

Rising Burden of Non-Communicable Diseases (NCDs): Increasing prevalence of chronic diseases like cardiovascular ailments, cancer, and diabetes requiring advanced medical interventions.

Demand for Quality Private Healthcare: A significant portion of the Indian population continues to seek private healthcare services due to perceived quality and accessibility issues in the public sector.

Risks

Global Health faces several risks:

Regulatory & Pricing Risks: Government interventions in pricing for certain procedures or drugs, and evolving regulatory landscape for the healthcare sector.

Intense Competition: Highly competitive market with established domestic players and potential entry of new large hospital chains.

Talent Attrition: Dependence on key medical professionals and the risk of losing talent to competitors.

High Capital Expenditure: Healthcare is a capital-intensive business, requiring significant ongoing investment in infrastructure, technology, and maintenance.

Healthcare Inflation: Rising costs of medical supplies, equipment, and highly skilled labor.

Ethical & Reputational Risks: Any lapse in patient care or ethical standards can severely impact brand image and patient trust.

Management & Ownership

Global Health Ltd. is promoted and led by Dr. Naresh Trehan, a renowned cardiac surgeon, who plays a pivotal role in the company's strategic direction and clinical excellence. The company operates with a professional management team overseeing its day-to-day operations and growth initiatives. The ownership structure includes the promoter group, private equity investors (prior to IPO), and public shareholders following its listing. Dr. Trehan's vision and clinical leadership are central to the company's identity and service quality.

Outlook

Global Health Ltd. operates in a structurally growing Indian healthcare market, benefiting from increasing demand for specialized medical care, rising affluence, and expanding insurance coverage. Its established brand, clinical expertise, and strategic expansion plans position it well to capture this growth. The company's focus on high-acuity, super-specialty services provides higher revenue per bed and strong clinical outcomes. However, the sector is inherently capital-intensive, subject to regulatory scrutiny (especially on pricing), and faces intense competition for both patients and medical talent. Maintaining clinical excellence, managing operational costs, and navigating potential government policy changes will be crucial for sustained profitability and market leadership. The outlook is cautiously optimistic, balancing robust growth opportunities against operational complexities and competitive pressures inherent in the private healthcare sector.

Global Health Share Price

Live · BSE / NSE · Inception: 2004
| |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Global Health Quarterly Results

#(Fig in Cr.) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 836 809 861 957 943 931 1031 1099 1121 1159
Other Income 18 27 22 18 16 23 20 20 22 37
Total Income 855 836 883 975 959 954 1051 1119 1143 1196
Total Expenditure 621 629 675 728 706 707 804 868 904 915
Operating Profit 234 207 208 247 254 248 247 251 239 281
Interest 18 18 18 16 16 15 14 17 22 27
Depreciation 44 45 47 49 48 49 45 50 61 67
Exceptional Income / Expenses 0 0 0 0 0 -50 20 16 -37 0
Profit Before Tax 172 143 144 181 189 133 208 200 120 187
Provision for Tax 49 16 37 50 46 32 49 41 25 46
Profit After Tax 124 127 106 131 143 101 159 158 95 142
Adjustments 0 0 0 0 0 0 0 0 -0 2
Profit After Adjustments 124 127 106 131 143 101 159 158 95 144
Adjusted Earnings Per Share 4.6 4.7 4 4.9 5.3 3.8 5.9 5.9 3.5 5.4

Global Health Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 1194 1382 1277 1343 1441 1500 1447 2167 2710 3275 3692 4410
Other Income 36 45 67 49 65 44 31 39 49 75 105 99
Total Income 1230 1427 1344 1392 1506 1544 1478 2206 2759 3350 3797 4509
Total Expenditure 932 1081 1155 1218 1299 1309 1250 1709 2074 2466 2832 3491
Operating Profit 299 347 189 174 207 235 228 497 686 884 965 1018
Interest 9 14 23 28 21 57 73 86 86 84 74 80
Depreciation 64 70 81 86 91 115 123 130 150 173 194 223
Exceptional Income / Expenses 0 0 -0 0 0 0 0 0 0 0 -50 -1
Profit Before Tax 226 262 85 60 95 64 32 281 449 627 647 715
Provision for Tax 79 92 35 27 34 28 4 84 123 149 166 161
Profit After Tax 147 170 51 33 61 36 29 196 326 478 481 554
Adjustments 1 0 0 -0 -0 0 0 0 0 0 0 2
Profit After Adjustments 147 170 51 33 61 36 29 196 326 478 481 556
Adjusted Earnings Per Share 6.2 7.1 2.1 1.4 2.5 1.5 1.2 7.7 12.2 17.8 17.9 20.7

Global Health Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 879 1057 1139 1217 1305 1350 1382 1616 2428 2906 3386
Minority's Interest 1 0 0 0 0 0 0 0 0 -0 1
Borrowings 40 113 132 336 589 606 578 768 737 283 264
Other Non-Current Liabilities 78 76 109 97 87 403 722 819 352 436 463
Total Current Liabilities 214 238 272 334 279 358 405 419 573 618 619
Total Liabilities 1212 1485 1653 1984 2259 2716 3087 3622 4090 4243 4733
Fixed Assets 752 914 972 1089 1030 1703 1616 1776 2050 2236 2514
Other Non-Current Assets 50 62 53 423 739 534 969 1034 461 498 686
Total Current Assets 410 509 627 472 490 479 502 812 1579 1509 1533
Total Assets 1212 1485 1653 1984 2259 2716 3087 3622 4090 4243 4733

Global Health Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 63 62 42 44 47 60 148 69 119 767 425
Cash Flow from Operating Activities 213 228 115 63 150 175 242 311 645 612 624
Cash Flow from Investing Activities -126 -241 -107 -69 -243 -87 -239 -421 -342 -441 -721
Cash Flow from Financing Activities -87 -7 -6 9 113 -1 -81 160 346 -514 -97
Net Cash Inflow / Outflow -0 -20 2 3 19 87 -78 50 648 -343 -194
Closing Cash & Cash Equivalent 62 43 44 47 66 148 69 119 767 425 230

Global Health Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 6.18 7.06 2.09 1.36 2.48 1.47 1.16 7.75 12.16 17.81 17.92
CEPS(Rs) 8.82 9.98 5.41 4.92 6.18 6.14 6.13 12.87 17.75 24.24 25.13
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0.5
Book NAV/Share(Rs) 35.31 41.99 43.89 45.79 49.62 51.42 53.14 63.6 90.35 108.05 126.07
Core EBITDA Margin(%) 21.99 21.81 9.57 9.33 9.87 12.77 13.61 21.14 23.48 24.7 23.3
EBIT Margin(%) 19.67 20 8.48 6.55 8.07 8.03 7.27 16.93 19.77 21.71 19.54
Pre Tax Margin(%) 18.92 18.97 6.68 4.44 6.61 4.26 2.24 12.95 16.58 19.15 17.53
PAT Margin (%) 12.28 12.32 3.96 2.45 4.23 2.42 1.99 9.05 12.03 14.6 13.04
Cash Profit Margin (%) 17.61 17.41 10.28 8.88 10.53 10.09 10.51 15.04 17.57 19.87 18.28
ROA(%) 12.1 12.62 3.23 1.81 2.88 1.46 0.99 5.85 8.46 11.47 10.72
ROE(%) 17.43 18.36 4.87 3.03 5.24 2.92 2.23 13.4 16.17 17.96 15.31
ROCE(%) 25.32 26.12 8.63 5.94 6.55 6.2 5.26 16.38 18.71 21.56 20.5
Receivable days 16.24 16.98 26.04 35.14 40.02 38.11 35.67 26.43 25.21 22.82 25.07
Inventory Days 7.73 7 7.02 6 5.83 7.52 9.87 7.84 7.66 7.09 6.62
Payable days 94.1 87.91 125.84 122.57 130.66 147.14 139.29 91.04 97.6 91.68 79.17
PER(x) 0 0 0 0 0 0 0 0 43.28 74.33 66.85
Price/Book(x) 0 0 0 0 0 0 0 0 5.82 12.25 9.5
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0.04
EV/Net Sales(x) -0.15 -0.12 -0.16 0.18 0.3 0.3 0.3 0.17 5.05 10.62 8.5
EV/Core EBITDA(x) -0.59 -0.47 -1.09 1.4 2.05 1.93 1.92 0.76 19.95 39.37 32.52
Net Sales Growth(%) 0 15.72 -7.59 5.17 7.29 4.11 -3.58 49.81 25.03 20.86 12.74
EBIT Growth(%) 0 17.7 -60.81 -18.78 32.26 3.49 -12.72 249.06 45.99 32.72 1.51
PAT Growth(%) 0 16.06 -70.26 -34.92 85.19 -40.45 -20.7 581.08 66.2 46.61 0.68
EPS Growth(%) 0 14.34 -70.43 -35.06 83.09 -40.68 -21.09 566.84 56.92 46.48 0.65
Debt/Equity(x) 0.06 0.13 0.17 0.37 0.49 0.48 0.48 0.52 0.35 0.14 0.1
Current Ratio(x) 1.92 2.14 2.31 1.41 1.76 1.34 1.24 1.94 2.76 2.44 2.48
Quick Ratio(x) 1.8 2.02 2.23 1.34 1.68 1.23 1.14 1.81 2.65 2.33 2.37
Interest Cover(x) 26.34 19.34 4.71 3.11 5.5 2.13 1.45 4.25 6.2 8.49 9.71
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0.06 0.01 0.01

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +13% +19% +20% +12%
Operating Profit CAGR +9% +25% +33% +12%
PAT CAGR +1% +35% +68% +13%
Share Price CAGR +4% +26%
ROE Average +15% +16% +13% +11%
ROCE Average +21% +20% +16% +15%

Global Health Shareholding Pattern

Latest · Mar 2026
100% held
Promoters 33.01 %
FII 10.15 %
DII (MF + Insurance) 14.76 %
Public (retail) 66.99 %
# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 33.0533.0433.0433.0433.0333.0333.0133.0133.0133.01
FII 11.3612.0912.9412.212.4711.7611.5411.410.5310.15
DII 11.1510.2510.5711.1110.5111.9312.212.981414.76
Public 66.9566.9666.9666.9666.9766.9766.9966.9966.9966.99
Others 0000000000
Total 100100100100100100100100100100

Global Health Peer Comparison

Hospital & Healthcare Services Edit Columns

Global Health Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Global Health Pros & Cons

Pros

  • Company has delivered good profit growth of 67% CAGR over last 5 years
  • Debtor days have improved from 91.68 to 79.17days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 33.01%.
  • Stock is trading at 8.4 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp